Relapsed or Refactory

Criteria to qualify for study: Drug used in study:
  • CD20 positive
  • Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.
  • Must have had at least one prior anti­cancer treatment.


An Open-Label, Phase lb Study of IPI-145 in combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with
Lymphoma or Chronic Lymphocytic Leukemia






Relapsed, Refactory or Untreated